Novo to buy Akero for up to $5.2 billion in new CEO’s revival push

Novo Nordisk is set to acquire Akero Therapeutics for up to $5.2 billion, marking a significant move under the leadership of its new CEO. This acquisition is expected to enhance Novo's portfolio in the biotechnology sector, particularly in developing treatments for liver diseases. The deal highlights Novo's commitment to innovation and growth, which could lead to improved patient outcomes and strengthen its position in the pharmaceutical market.